profit from every $100 of sales.
$0$100
Aspire Biopharma Holdings
$8.51+5.19% today
-97.0% in 1 year
1-year low $4.651-year high $288.00
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Aspire Biopharma Holdings sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $6,202 in 2025, with -$24.5 million of profit last year.
SalesProfit
Aspire Biopharma Holdings vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Aspire Biopharma Holdings | No profit yet | ||
 Vertex Pharmaceuticals | 35.3× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.1× · Fair price | ||
 CSL | 22.2× · Fair price |
AI analysis
An AI analyst reads Aspire Biopharma Holdings's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| 0 | 0 | 0 | -0 | |
| -1 | -1 | -1 | -19 | |
| -1 | 4 | -1 | -16 | |
| -1 | 4 | -1 | -24 | |
| -15.57 | 116.44 | -34.17 | -491.40 | |
| – | – | – | -1.9% | |
| – | – | – | -312,016.9% | |
| – | – | – | -394,725.1% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 0 | 0 | 0 | 1 |
| Cash | 0 | 0 | 0 | 1 |
| Total debt | 0 | 0 | 1 | 5 |
| Total liabilities | 0 | 1 | 2 | 8 |
| -0 | -0 | -2 | -6 | |
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| 463.6% | -915.0% | 85.1% | 383.9% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -0 | 0 | -0 | -5 | |
| 5 | 0 | – | – | |
| -5 | 0 | -0 | -5 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| – | – | 0 | 14 |
Valuation
- –
- –
- –
- 0.2×
- 1,924.5×
- –
- –
- -41.2%
- -205.1%
- 0.0%
Profitability
- -1.9%
- -312,016.9%
- -394,725.1%
- -15,471.2%
- -121.9%
- 1,018.3%
- 199.4%
- -165.3%
- -137.2%
- 2,771.1%
Growth
- –
- –
- −1,756.6%
- –
- +21.6%
Financial health
- –
- 0.13
- 7.0%
- -0.8×
- 2.26
- 2.14
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 1%of 985
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 15, 2026 | -20.57 | – | – |
| Mar 30, 2026 | -3.15 | – | – |
| Nov 14, 2025 | -0.04 | – | – |
| Aug 13, 2025 | -0.04 | – | – |
| May 14, 2025 | -16.80 | – | – |
| Apr 7, 2025 | -0.28 | – | – |
| Nov 14, 2024 | -0.02 | – | – |
| Aug 16, 2024 | -0.02 | – | – |
News
Acurx outlines 20-patient PATHFINDER start in Q4 as FDA stays open to a single Phase III ASPIRE for ibezapolstatSeeking Alpha · Aug 14, 2026The newest story we have is from Aug 14, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/6Passes 1 of 6. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
12No pass
Benjamin Graham
73Pass
Philip Fisher
25No pass
Peter Lynch
–Not enough data
Joel Greenblatt
2No pass
Charlie Munger
22No pass
Terry Smith
18No pass
Questions about Aspire Biopharma Holdings
Is Aspire Biopharma Holdings a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 6 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Aspire Biopharma Holdings AI analysis
What does Aspire Biopharma Holdings do?
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It is in Biotechnology.
Does Aspire Biopharma Holdings pay a dividend?
No. Aspire Biopharma Holdings does not pay a dividend at the moment.
Is Aspire Biopharma Holdings stock halal?
No. Aspire Biopharma Holdings does not pass our halal screen: its debt is 43% of its market value, at or above the 33% limit. How we check
How has Aspire Biopharma Holdings stock done over the past year?
Down 97.0% over the past twelve months, to $8.51. It traded between $4.65 and $288.00 and is 97.0% below its high.
Who are Aspire Biopharma Holdings's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Aspire Biopharma Holdings's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.